Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation

European Journal of Cancer

Volumn 48, Issue 1, 2012, Pages 12-23

  Karn, Thomas ^a   Pusztai, Lajos ^b   Ruckhäberle, Eugen ^a   Liedtke, Cornelia ^c   Müller, Volkmar ^d   Schmidt, Marcus ^e   Metzler, Dirk ^f   Wang, Jing ^b   Coombes, Kevin R ^b   Gätje, Regine ^a   Hanker, Lars ^a   Solbach, Christine ^a   Ahr, Andre ^a   Holtrich, Uwe ^a   Rody, Achim ^a   Kaufmann, Manfred ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f UNIVERSITY OF MUNICH   (Germany)

Author keywords

Bimodal expression; CT X antigens; Immune therapy; Microarray analysis; Prognostic markers; Subtypes of breast cancer

Indexed keywords

CANCER TESTIS ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MELANOMA ANTIGEN;

ARTICLE; BIMODALITY INDEX; BIOINFORMATICS; CANCER CLASSIFICATION; CANCER SURVIVAL; CORRELATION ANALYSIS; DRUG TARGETING; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; TRIPLE NEGATIVE BREAST CANCER; TUMOR MICROENVIRONMENT;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; BREAST NEOPLASMS; CANCER VACCINES; CARCINOMA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEALTH STATUS INDICATORS; HUMANS; IMMUNOTHERAPY; MELANOMA-SPECIFIC ANTIGENS; MICROARRAY ANALYSIS; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 83255185240     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.06.025     Document Type: Article

References (50)

1. A. Ertel, and A. Tozeren Switch-like genes populate cell communication pathways and are enriched for extracellular proteins BMC Genomics 9 2008 3
2. A.E. Teschendorff, A. Naderi, N.L. Barbosa-Morais, and C. Caldas PACK: Profile Analysis using Clustering and Kurtosis to find molecular classifiers in cancer Bioinformatics 22 18 2006 2269 2275
3. A.E. Teschendorff, A. Miremadi, S.E. Pinder, I.O. Ellis, and C. Caldas An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer Genome Biol 8 8 2007 R157
4. A. Ertel Bimodal gene expression and biomarker discovery Cancer Inform 9 2010 11 14
5. J. Wang, S. Wen, W.F. Symmans, L. Pusztai, and K.R. Coombes The bimodality index: a criterion for discovering and ranking bimodal signatures from cancer gene expression profiling data Cancer Inform 7 2009 199 216
6. T. Karn, D. Metzler, and E. Ruckhäberle Data driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer Breast Cancer Res Treat 45 2009 5
7. C. Sotiriou, and L. Pusztai Gene-expression signatures in breast cancer N Engl J Med 360 8 2009 790 800
8. P. Wirapati, C. Sotiriou, and S. Kunkel Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures Breast Cancer Res 10 4 2008 R65
9. A. Tabchy, V. Valero, and T. Vidaurre Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer Clin Cancer Res 16 21 2010 5351 5361
10. A.J. Simpson, O.L. Caballero, A. Jungbluth, Y.T. Chen, and L.J. Old Cancer/testis antigens, gametogenesis and cancer Nat Rev Cancer 5 8 2005 615 625
11. M.J. Scanlan, A.O. Gure, A.A. Jungbluth, L.J. Old, and Y.T. Chen Cancer/testis antigens: an expanding family of targets for cancer immunotherapy Immunol Rev 188 2002 22 32 [Review]
12. N. Van Baren, M.C. Bonnet, and B. Dréno Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells J Clin Oncol 23 35 2005 9008 9021
13. L.M. McShane, D.G. Altman, and W. Sauerbrei Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies J Clin Oncol 23 36 2005 9067 9072
14. Affymetrix (2001) Statistical algorithms reference guide, Technical report, Affymetrix.
15. L. Gautier, L. Cope, B.M. Bolstad, and R.A. Irizarry Affy - analysis of Affymetrix GeneChip data at the probe level Bioinformatics 20 3 2004 307 315
16. R.C. Gentleman, V.J. Carey, and D.M. Bates Bioconductor: open software development for computational biology and bioinformatics Genome Biol 5 10 2004 R80
17. C.M. Perou, T. Sørlie, and M.B. Eisen Molecular portraits of human breast tumours Nature 406 6797 2000 747 752
18. P. Farmer, H. Bonnefoi, and V. Becette Identification of molecular apocrine breast tumours by microarray analysis Oncogene 24 29 2005 4660 4671
19. A.S. Doane, M. Danso, and P. Lal An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen Oncogene 25 28 2006 3994 4008
20. A. Rody, U. Holtrich, and L. Pusztai T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers Breast Cancer Res 11 2 2009 R15
21. C. Desmedt, B. Haibe-Kains, and P. Wirapati Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes Clin Cancer Res 14 16 2008 5158 5165
22. M. Schmidt, D. Böhm, and C. von Törne The humoral immune system has a key prognostic impact in node-negative breast cancer Cancer Res 68 13 2008 5405 5413
23. G. Bianchini, Y. Qi, and R.H. Alvarez Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers J Clin Oncol 28 28 2010 4316 4323
24. P. Farmer, H. Bonnefoi, and P. Anderle A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer Nat Med 15 1 2009 68 74
25. B.T. Hennessy, A.M. Gonzalez-Angulo, and K. Stemke-Hale Characterization of a naturally occurring breast cancer subset enriched in epithelial-to- mesenchymal transition and stem cell characteristics Cancer Res 69 10 2009 4116 4124
26. C.J. Creighton, X. Li, and M. Landis Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features Proc Natl Acad Sci USA 106 33 2009 13820 13825
27. A.R. Whitney, M. Diehn, and S.J. Popper Individuality and variation in gene expression patterns in human blood Proc Natl Acad Sci USA 100 4 2003 1896 1901
28. Z. Hu, C. Fan, and C. Livasy A compact VEGF signature associated with distant metastases and poor outcomes BMC Med 6 2009 7 9
29. I. Biche, C. Chavey, and C. Andrieu CXC chemokines located in the 4q21 region are up-regulated in breast cancer Endocr Relat Cancer 14 4 2007 1039 1052
30. Rody A, Karn T, Liedtke C, et al. Identification of a clinically relevant gene signature in triple negative and basal-like breast cancer. Cancer Res 2010;70(Suppl. 24) [Abstract No. S5-5].
31. A. Mischo, B. Kubuschok, and K. Ertan Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer Int J Cancer 118 3 2006 696 703
32. D. Bandić, A. Juretić, and B. Sarcević Expression and possible prognostic role of MAGE-A4, NY-ESO-1 and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study Croat Med J 47 1 2006 32 41
33. M. Taylor, L.M. Bolton, P. Johnson, T. Elliott, and N. Murray Breast cancer is a promising target for vaccination using cancer-testis antigens known to elicit immune responses Breast Cancer Res 9 4 2007 R46
34. Y. Sugita, H. Wada, and S. Fujita NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors Cancer Res 64 6 2004 2199 2204
35. M. Otte, M. Zafrakas, and L. Riethdorf MAGE-A gene expression pattern in primary breast cancer Cancer Res 61 18 2001 6682 6687
36. J.P. Theurillat, F. Ingold, and C. Frei NY-ESO-1 protein expression in primary breast carcinoma and metastases: correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration Int J Cancer 120 11 2007 2411 2417
37. A. Grigoriadis, O.L. Caballero, and K.S. Hoek CT-X antigen expression in human breast cancer Proc Natl Acad Sci USA 106 32 2009 13493 13498
38. A.O. Gure, R. Chua, and B. Williamson Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer Clin Cancer Res 11 22 2005 8055 8062
39. L.A. Carey, E.C. Dees, and L. Sawyer The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 8 2007 Apr 2329 2334
40. W.J. Irvin Jr, and L.A. Carey What is triple-negative breast cancer? Eur J Cancer 44 18 2008 2799 2805
41. A. Bender, J. Karbach, and A. Neumann LUD 00-009 phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer Cancer Immun 7 2007 16
42. D. Atanackovic, N.K. Altorki, and Y. Cao Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming Proc Natl Acad Sci USA 105 5 2008 1650 1655
43. E. Jager, J. Karbach, and S. Gnjatic Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients Proc Natl Acad Sci USA 103 39 2006 14453 14458
44. D. Valmori, N.E. Souleimanian, and V. Tosello Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming Proc Natl Acad Sci USA 104 21 2007 8947 8952
45. K. Odunsi, F. Qian, and J. Matsuzaki Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer Proc Natl Acad Sci USA 104 31 2007 12837 12842
46. I.D. Davis, W. Chen, and H. Jackson Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans Proc Natl Acad Sci USA 101 29 2004 10697 10702
47. A.M. Eggermont, A. Testori, M. Maio, and C. Robert Anti-CTLA-4 antibody adjuvant therapy in melanoma Semin Oncol 37 5 2010 455 459 Review
48. L. Calabro, R. Danielli, L. Sigalotti, and M. Maio Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications Semin Oncol 37 5 2010 460 467
49. B.C. Carthon, J.D. Wolchok, and J. Yuan Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial Clin Cancer Res 16 10 2010 2861 2871
50. R.H. Vonderheide, P.M. LoRusso, and M. Khalil Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells Clin Cancer Res 16 13 2010 3485 3494